Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 7/20 | 0.40 |
| ▸ | BCHE | P06276 | 9/20 | 0.35 |
| ▸ | ACHE | P22303 | 9/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62946 | 0.93 | C5AR1 (0.43) | C5AR1BCHEACHE | |
| SCHEMBL61870 | 0.92 | C5AR1 (0.48) | C5AR1BCHEACHE | |
| SCHEMBL61659 | 0.87 | C5AR1 (0.37) | C5AR1BCHEACHEL3MBTL1 | |
| SCHEMBL62140 | 0.87 | C5AR1 (0.54) | C5AR1BCHEACHE | |
| SCHEMBL62072 | 0.87 | C5AR1 (0.54) | C5AR1BCHEACHE | |
| SCHEMBL27666466 | 0.86 | C5AR1 (0.36) | C5AR1BCHEACHEL3MBTL1 | |
| SCHEMBL63332 | 0.86 | BCHE (0.36) | C5AR1BCHEACHEL3MBTL1 | |
| SCHEMBL72378 | 0.85 | C5AR1 (0.49) | C5AR1BCHEACHE | |
| SCHEMBL62043 | 0.84 | BCHE (0.36) | C5AR1BCHEACHEL3MBTL1 | |
| SCHEMBL62487 | 0.83 | BCHE (0.35) | C5AR1BCHEACHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1976918-A | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORP (US) | 2007-06-06 | — | — | CN | claimed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C5AR1, C3AR1 | C5AR1 2/4885BCHE 3849/4885ACHE 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.